Experimental combo aims to tackle tough bone cancer
NCT ID NCT07144254
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called tegavivint combined with the chemotherapy gemcitabine in 24 people whose osteosarcoma (a type of bone cancer) has returned or not responded to prior treatment. The main goal is to find the safest dose of tegavivint when given with gemcitabine, and to see if the combination can control the disease. Participants receive the drugs intravenously over several weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tegavivint and gemcitabine
What this could lead to
If successful, this could lead to a new treatment option for patients with osteosarcoma that has come back or not responded to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, focused on finding a safe dose. It is not yet known if the combination will effectively control the cancer, and side effects may be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Arthur M. Blank Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
Contact